Seres Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Seres Therapeutics

05/03/2024 23:45

* Seres Therapeutics Inc  MCRB.OQ  reported a quarterly
adjusted
loss of 32 cents​​ per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of -54 cents.  The mean expectation of
seven analysts for the quarter was for a loss of 50 cents per
share. Wall Street expected results to range from -100 cents
to -33 cents per share.
    * Revenue fell 93.6% to $64.00 thousand from a year ago;
analysts
expected $350.00 thousand. 
    * Seres Therapeutics Inc's reported EPS for the quarter was
a loss
of 32 cents​.
    * The company reported a quarterly loss of $41.25 million.
    * Seres Therapeutics Inc shares had fallen by 18.6% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 0.9%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Seres
Therapeutics Inc is $10.00 
This summary was machine generated from LSEG data March 5 at
11:44 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.50          -0.32          Beat
 Sep. 30 2023      -0.50          -0.37          Beat
 Jun. 30 2023      0.53           0.36           Missed
 Mar. 31 2023      -0.55          -0.57          Missed